A Phase 2 interventional study of AK102 and Statins in Homozygous Familial Hypercholesterolemia, sponsored by Akeso. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.
Sponsored by Akeso · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.
Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 2nd registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 12–55
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 12+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5
First in 2001; this study’s year is marked. 3 started in 2019.
This study's enrollment of 10 is below the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 20 across the 11 interventional studies, 5 across the 1 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Akeso has 1 study filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
2 of the studies in Homozygous Familial Hypercholesterolemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125847First Affiliated Hospital Xi'an Jiaotong UniversityNGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia | 2027-03-30 |
| NCT07591298CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia | 2027-09-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts, part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of PCSK9 inhibitor AK102, and part 2 is double blind, randomized, placebo controlled study to evaluate the efficacy and safety of PCSK9 inhibitor AK102. The treatment period will last 12 week.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
450mg AK102, Q4W, subcutaneous injection
Drug: AK102 · Drug: Statins · Drug: Ezetimibe
Placebo, Q4W, subcutaneous injection
Drug: Statins · Drug: Ezetimibe
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Time frame: Week 12
Incidence of treatment-emergent adverse events as assessed by CTCAE V5.0(only for part 1)
Time frame: From baseline through 12 weeks
Percent Change From Baseline in High-density lipoprotein (HDL) cholesterol
Time frame: From baseline through 12 weeks
Percent Change From Baseline in non High-density lipoprotein (non-HDL) cholesterol
Time frame: From baseline through 12 weeks
Percent Change From Baseline in Serum Triglyceride (TG)
Time frame: From baseline through 12 weeks
Percent Change From Baseline in Apolipoprotein B (Apo B)
Time frame: From baseline through 12 weeks
Percent Change From Baseline in Apolipoprotein A-I (Apo A-I)
Time frame: From baseline through 12 weeks
Percent Change From Baseline in Total Cholesterol(TC)
Time frame: From baseline through 12 weeks
Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Time frame: From baseline through 12 weeks
Concentrations of AK102 in Serum
Time frame: Part 1: Day 1,Day 2, Day 4, Day 8, Day 15, Day 22, D29, D57. Part 2: Day 1, Day 29, Day 57
Number of subjects who develop detectable anti-drug antibodies (ADAs)
Time frame: From baseline through 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2019 to primary completion in Mar 2021, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ebronucimab
Homozygous Familial Hypercholesterolemia →